Risk of VTE Associated With Tofacitinib in Patients With RA Risk of VTE Associated With Tofacitinib in Patients With RA
Does tofacitinib treatment increase the risk for venous thromboembolism in patients with rheumatoid arthritis?Rheumatology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 2, 2022 Category: Intensive Care Tags: Rheumatology Journal Article Source Type: news
Developmental Hemostasis: The Evolution of our Coagulation System
Developmental hemostasis describes the evolution of the coagulation system from the neonatal period through adulthood. Neonates have lower levels of coagulation factors and elevated screening levels at birth. These levels can be influenced by various circumstances including gestational age, labor effects, and clinical status. The most commonly used screening tests for coagulopathy are the prothrombin time, partial thromboplastin time, and fibrinogen level. These values can be difficult to interpret as every laboratory has its own age-specific reference ranges. An understanding of developmental hemostasis is important when ...
Source: NeoReviews recent issues - February 1, 2022 Category: Pediatrics Source Type: news
Thrombosis, Thrombocytopenia Syndrome Up After Ad26.COV2.S
Reporting rates 3.83 per million vaccine doses for Ad26.COV2.S versus 0.00855 per million for mRNA - based vaccines (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 28, 2022 Category: Cancer & Oncology Tags: Family Medicine, Infections, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news
Thrombosis, Thrombocytopenia Syndrome Up After Ad26.COV2.S
FRIDAY, Jan. 28, 2022 -- The rate of thrombosis with thrombocytopenia syndrome (TTS) is higher after receipt of the Ad26.COV2.S vaccine than mRNA-based COVID-19 vaccines, according to a case series published online Jan. 18 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 28, 2022 Category: Pharmaceuticals Source Type: news
Prolonged TV Watching Ups Blood Clot Risk
35 percent higher risk for venous thromboembolism seen with watching more than four hours of TV daily (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 22, 2022 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Journal, Source Type: news
Prolonged TV Watching Ups Blood Clot Risk
FRIDAY, Jan. 21, 2022 -- Prolonged television watching increases the risk for venous thromboembolism (VTE), according to a systematic review and meta-analysis published online Jan. 20 in the European Journal of Preventive Cardiology.
Setor K.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2022 Category: Pharmaceuticals Source Type: news
DOACs Should Be Standard of Care in Cancer-Associated Thrombosis DOACs Should Be Standard of Care in Cancer-Associated Thrombosis
Direct oral anticoagulants are more effective than dalteparin in reducing the risk of thrombosis recurrence without significantly increasing the risk of major bleeding.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 21, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Blood clots: Four skin changes in the arms and legs that are warning signs
DEEP vein thrombosis is a type of blood clot that develops in the legs or arms. The "dangerous" condition might require a prompt call to 999, so be aware of the warning signs. (Source: Daily Express - Health)
Source: Daily Express - Health - January 19, 2022 Category: Consumer Health News Source Type: news
Incoming NHS England chair Richard Meddings admits he has used private healthcare
Former banker Richard Medding, 63 - who is Sajid Javid's pick to chair the NHS - revealed he chose to use private health care 'late last year' when being treated for deep vein thrombosis. (Source: the Mail online | Health)
Source: the Mail online | Health - January 18, 2022 Category: Consumer Health News Source Type: news
Direct oral anticoagulants significantly decrease recurrent venous thrombosis for adult cancer patients, Mayo Clinic study finds
ROCHESTER, Minn. — Direct oral anticoagulants should be considered the standard of care to treat adult patients with cancer-associated thrombosis, according to a new, ongoing study by Mayo Clinic researchers. Thrombosis is a condition where blood clots form in blood vessels of the legs. These clots can travel to t he lungs and become lodged in blood vessels, causing a pulmonary embolism. Thrombotic outcomes increase mortality in cancer patients and are the second most common cause of… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - January 18, 2022 Category: Research Source Type: news
Shorter Course of Anticoagulant Therapy Adequate for Provoked VTE in Children Shorter Course of Anticoagulant Therapy Adequate for Provoked VTE in Children
For children with acute provoked venous thromboembolism, 6 weeks of anticoagulant therapy is as effective as a three-month course of anticoagulant therapy, results of a new clinical trial suggest.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 13, 2022 Category: Intensive Care Tags: Critical Care News Source Type: news
Rivaroxaban Improves Clinical Outcomes After COVID-19 Hospitalization
THURSDAY, Dec. 30, 2021 -- For patients at high risk for venous thromboembolism (VTE) discharged after COVID-19 hospitalization, thromboprophylaxis with rivaroxaban is associated with improved clinical outcomes, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 30, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization
A randomized, open-label trial showed improved clinical outcomes from a low dose of direct oral anticoagulant in patients at high risk for venous thromboembolism and low risk for bleeding.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 17, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Prevention and management of venous thromboembolism in COVID-19, Scottish Intercollegiate Guidelines Network
Guideline provides recommendations based on current evidence for best practice in pharmacological prophylaxis& management of thrombotic complications of all degrees of severity of COVID-19, including advice for non-pregnant adults in ICU and non-ICU settings and in the community. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 17, 2021 Category: Consumer Health News Source Type: news
